- Home
- CMPX vs TLSI Comparison
CMPX vs TLSI Comparison
Compare CMPX & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- TLSI
- Stock Information
- Founded
- CMPX 2014
- TLSI 2010
- Country
- CMPX United States
- TLSI United States
- Employees
- CMPX N/A
- TLSI N/A
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- TLSI Medical Specialities
- Sector
- CMPX Health Care
- TLSI Health Care
- Exchange
- CMPX Nasdaq
- TLSI Nasdaq
- Market Cap
- CMPX 217.4M
- TLSI 166.8M
- IPO Year
- CMPX N/A
- TLSI N/A
- Fundamental
- Price
- CMPX $1.73
- TLSI $4.59
- Analyst Decision
- CMPX Strong Buy
- TLSI Strong Buy
- Analyst Count
- CMPX 3
- TLSI 3
- Target Price
- CMPX $7.67
- TLSI $12.67
- AVG Volume (30 Days)
- CMPX 417.8K
- TLSI 73.9K
- Earning Date
- CMPX 11-07-2024
- TLSI 11-12-2024
- Dividend Yield
- CMPX N/A
- TLSI N/A
- EPS Growth
- CMPX N/A
- TLSI N/A
- EPS
- CMPX N/A
- TLSI N/A
- Revenue
- CMPX $850,000.00
- TLSI $24,736,000.00
- Revenue This Year
- CMPX N/A
- TLSI $61.24
- Revenue Next Year
- CMPX $950.68
- TLSI $47.32
- P/E Ratio
- CMPX N/A
- TLSI N/A
- Revenue Growth
- CMPX N/A
- TLSI 67.75
- 52 Week Low
- CMPX $0.77
- TLSI $3.32
- 52 Week High
- CMPX $2.34
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- CMPX 66.59
- TLSI 34.61
- Support Level
- CMPX $1.42
- TLSI $4.54
- Resistance Level
- CMPX $1.86
- TLSI $5.08
- Average True Range (ATR)
- CMPX 0.15
- TLSI 0.35
- MACD
- CMPX 0.01
- TLSI -0.04
- Stochastic Oscillator
- CMPX 70.14
- TLSI 15.79
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.